Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients

Authors
Category Primary study
JournalJournal of the Endocrine Society
Year 2022
This article has no abstract
Epistemonikos ID: 67a42f807a7336cbfb9337c23a1df558e30133f8
First added on: Apr 29, 2024